PPARA and neoplasm: Acknowledging the limitation of small patient numbers, these response data in immunotherapy-refractory patients are consistent with the preclinical results showing that TPST-1120 modulates the immune phenotype away from suppressor populations and combines synergistically with anti-PD-1 therapy (16), and consistent with the literature that genetic KO of PPARα increases inflammation and decreases tumor growth in mouse models (14).